CEL-SCI Corporation
(NYSE Amex Equities : CVM)

( )
CVM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.31%86.001.3%$1325.78m
AMGNAmgen Inc.
-0.93%201.981.2%$608.04m
GILDGilead Sciences, Inc.
-0.91%68.550.9%$534.22m
LOXOLoxo Oncology Inc
0.12%233.7812.7%$511.41m
BIIBBiogen Inc.
0.46%338.961.3%$413.85m
VRTXVertex Pharmaceuticals Incorporated
-0.42%193.881.9%$324.40m
ILMNIllumina, Inc.
-2.92%303.623.5%$304.88m
REGNRegeneron Pharmaceuticals, Inc.
-3.36%404.752.6%$294.14m
ALXNAlexion Pharmaceuticals, Inc.
-2.36%114.292.0%$213.93m
INCYIncyte Corporation
-1.39%77.332.5%$145.56m
AAgilent Technologies, Inc.
-0.89%71.291.5%$145.13m
EXASExact Sciences Corporation
-3.46%76.0725.3%$135.78m
SRPTSarepta Therapeutics, Inc.
-2.05%120.2815.4%$130.09m
LGNDLigand Pharmaceuticals Incorporated
-4.23%112.9123.1%$119.15m
NBIXNeurocrine Biosciences, Inc.
-0.27%91.285.1%$97.05m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.